INTELLIA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 Oct 2024 08:46:04 By NetDania Notify

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 Oct 2024 07:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 Oct 2024 08:45:05 By NetDania Notify

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 Oct 2024 09:23:57 By NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 Oct 2024 08:45:08 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 Oct 2024 08:45:32 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 Oct 2024 12:25:49 By NetDania Notify

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 Sep 2024 09:45:32 By NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 Sep 2024 09:37:45 By NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

01 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

24 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces CFO Transition

26 Jun 2024 06:30:00 By Nasdaq GlobeNewswire